Patents by Inventor Kirsty Houslay

Kirsty Houslay has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • IL33 ANTIBODIES AND METHODS OF USING THE SAME
    Publication number: 20240016929
    Abstract: The present invention provides isolated IL-33 proteins, active fragments thereof and antibodies, antigen binding fragments thereof, against IL-33 proteins. Also provided are methods of modulating cytokine activity, e.g., for the purpose of treating immune and inflammatory disorders.
    Type: Application
    Filed: July 5, 2023
    Publication date: January 18, 2024
    Inventors: Emma S. COHEN, David C. LOWE, Robin BUTLER, Ian C. SCOTT, Katherine A. VOUSDEN, Martin D. STRAIN, Sara CARMEN, Elizabeth H. ENGLAND, Benjamin P. KEMP, David G. REES, Catherine L. OVERED-SAYER, Tomas M. MUSTELIN, Matthew SLEEMAN, Kirsty HOUSLAY
  • Polynucleotides encoding IL33 antibodies and methods of using the same
    Patent number: 11738081
    Abstract: The present invention provides isolated IL-33 proteins, active fragments thereof and antibodies, antigen binding fragments thereof, against IL-33 proteins. Also provided are methods of modulating cytokine activity, e.g., for the purpose of treating immune and inflammatory disorders.
    Type: Grant
    Filed: April 10, 2020
    Date of Patent: August 29, 2023
    Assignee: MEDIMMUNE LIMITED
    Inventors: Emma S. Cohen, David C. Lowe, Robin Butler, Ian C. Scott, Katherine A. Vousden, Martin D. Strain, Sara Carmen, Elizabeth H. England, Benjamin P. Kemp, David G. Rees, Catherine L. Overed-Sayer, Tomas M. Mustelin, Matthew Sleeman, Kirsty Houslay
  • METHODS OF USING IL-33 ANTAGONISTS
    Publication number: 20220380450
    Abstract: The present disclosure relates to an IL-33 antagonist for use in the prevention or treatment of abnormal epithelium physiology or EGFR-mediated diseases, and corresponding methods of prevention or treatment comprising administering an IL-33 antagonist to a patient in need thereof.
    Type: Application
    Filed: November 3, 2020
    Publication date: December 1, 2022
    Inventors: Rania DAGHER, Kirsty HOUSLAY, Mahboobe GHAEDI, Sam STRICKSON, Emma Suzanne COHEN, Maria BELVISI, Xavier ROMERO ROS
  • ANTI IL-33 THERAPEUTIC AGENT FOR TREATING RENAL DISORDERS
    Publication number: 20220363748
    Abstract: present disclosure relates to a method of treating kidney injury, by administering an anti-IL-33 therapeutic agent which inhibits both ST2 signaling and RAGE signaling.
    Type: Application
    Filed: November 3, 2020
    Publication date: November 17, 2022
    Inventors: David James BAKER, Carol Patricia MORENO QUINN, Kevin James WOOLLARD, Asha SETH, Elena LIARTE MARIN, Barbara MUSIAL, Emma Suzanne COHEN, Sam STRICKSON, Kirsty HOUSLAY
  • NOVEL IL33 FORM, MUTATED FORMS OF IL33, ANTIBODIES, ASSAYS AND METHODS OF USING THE SAME
    Publication number: 20200353078
    Abstract: The present invention provides isolated IL-33 proteins, active fragments thereof and antibodies, antigen binding fragments thereof, against IL-33 proteins. Also provided are methods of modulating cytokine activity, e.g., for the purpose of treating immune and inflammatory disorders.
    Type: Application
    Filed: April 10, 2020
    Publication date: November 12, 2020
    Inventors: Emma S. Cohen, David C. Lowe, Robin Butler, Ian C. Scott, Katherine A. Vousden, Martin D. Strain, Sara Carmen, Elizabeth H. England, Benjamin P. Kemp, David G. Rees, Catherine L. Overed-Sayer, Tomas M. Mustelin, Matthew Sleeman, Kirsty Houslay
  • IL33 form, mutated forms of IL33, antibodies, assays and methods of using the same
    Patent number: 10668150
    Abstract: The present invention provides isolated IL-33 proteins, active fragments thereof and antibodies, antigen binding fragments thereof, against IL-33 proteins. Also provided are methods of modulating cytokine activity, e.g., for the purpose of treating immune and inflammatory disorders.
    Type: Grant
    Filed: March 30, 2016
    Date of Patent: June 2, 2020
    Assignee: MEDIMMUNE LIMITED
    Inventors: Emma S. Cohen, David C. Lowe, Robin Butler, Ian C. Scott, Katherine A. Vousden, Martin D. Strain, Sara Carmen, Elizabeth H. England, Benjamin P. Kemp, David G. Rees, Catherine L. Overed-Sayer, Tomas M. Mustelin, Matthew Sleeman, Kirsty Houslay
  • A NOVEL IL33 FORM, MUTATED FORMS OF IL33, ANTIBODIES, ASSAYS AND METHODS OF USING THE SAME
    Publication number: 20180207265
    Abstract: The present invention provides isolated IL-33 proteins, active fragments thereof and antibodies, antigen binding fragments thereof, against IL-33 proteins. Also provided are methods of modulating cytokine activity, e.g., for the purpose of treating immune and inflammatory disorders.
    Type: Application
    Filed: March 30, 2016
    Publication date: July 26, 2018
    Inventors: Emma S. Cohen, David C. Lowe, Robin Butler, Ian C. Scott, Katherine A. Vousden, Martin D. Strain, Sara Carmen, Elizabeth H. England, Benjamin P. Kemp, David G. Rees, Catherine L. Overed-Sayer, Tomas M. Mustelin, Matthew Sleeman, Kirsty Houslay